CeMM: Diagenode licenses new ChIPmentation technology for low input library preparation for ChIP-sequencing

Diagenode, a leading global provider for complete solutions for sample preparation and epigenetics research, has licensed a new technology specific for ChIP-sequencing from the CeMM for low input samples.

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) allows the study of histone modifications and transcription factor binding on a genome-wide scale. However, ChIP from low input, biologically-relevant samples is challenging. Researchers in Christoph Bock’s group at CeMM have developed an efficient alternative to ChIP-seq that addresses these limitations, which they have coined “ChIPmentation.”

In ChIPmentation, ChIP and library preparation for sequencing can be accomplished concurrently using a transposase, that allows the incorporation of sequencing adaptors on the immunoprecipitated chromatin directly. This approach streamlines the ChIP-seq workflow to make the study of chromatin from rare and difficult cell types possible. The lab’s work was published in Nature Methods article “ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors.”

Diagenode’s license terms with the CeMM include acquiring quality procedures and expertise for ChIPmentation libraries and sequencing as well as bioinformatics analysis know-how.

“Our license agreement with the CeMM for ChIPmentation will bring ChIP-seq to new frontiers and reinforces our commitment to furthering epigenetics research,” said Didier Allaer, CEO of Diagenode. “We will be incorporating the ChIPmentation technology into Diagenode’s Epigenomic Profiling Services upon launch later this year. Researchers will finally be able to address epigenetics profiling with difficult samples, biopsies, and other patient-derived samples.”

In addition, the company is developing an automated library preparation method using ChIPmentation on its signature automation instrument the IP-StarⓇ Compact Automated System. This strategy further streamlines ChIP-seq by incorporating ChIP and library preparation more effectively and efficiently.

“We are very excited about our collaboration with Diagenode,” said Christoph Bock of the CeMM. “Diagenode has a long history of proficiency in developing innovative technologies for epigenetics research.”


Press contact
Mag. Wolfgang Däuble
Media Relations Manager
CeMM
Research Center for Molecular Medicine
of the Austrian Academy of Sciences
Tel: +43 (0)1 40160-70 057
Fax: +43 (0)1 40160-970 000
Email: wdaeuble(at)cemm.oeaw.ac.at
Web: www.cemm.at

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.